About the Marlene and Stewart Greenebaum Comprehensive Cancer Center

UMGCCCThe University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is one of the top cancer treatment and research centers in the country. In 2016, the National Cancer Institute elevated UMGCCC to its designation as a comprehensive cancer center — one of only 49 in the nation. As part of the University of Maryland Medical Center, we offer innovative approaches to diagnosing and treating all types of cancer, conduct cutting-edge research to bring the latest advances in cancer treatment directly to our patients, and provide cancer screening and patient education services.



Our National Profile

In 2016, UMGCCC became a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center, a distinction shared by just 49 centers across the US.

UMGCCC is ranked among the top 50 cancer programs in the country, according to U.S. News & World Report’s Best Hospitals list.

Cancer research funding at UMGCCC has grown dramatically since 2002 — from $19.4 million to $75.4 million — and continues to drive scientific discovery by our cancer experts, all of whom are faculty of the UM School of Medicine.

UMGCCC is a leader in addressing cancer disparities, with research focused on improving access to care and treatment outcomes for minorities, who represent 37 percent of the patients in our clinical trials, compared to 16 percent nationally.

The Maryland Proton Treatment Center, a next-generation radiation treatment facility, began treating patients in 2016 in the University of Maryland BioPark. Because of its precision, proton therapy is thought to be beneficial for some patients with tumors near vital organs, as well as for pediatric patients.

UMGCCC is a national leader in developing new immunotherapy approaches that train a patient’s own immune system to fight cancer. More than 30 clinical trials at UMGCCC currently utilize immunotherapy. These trials will soon be supported by UMGCCC’s building of a state-of-the-art GMP (Good Manufacturing Practice) Lab, where researchers will genetically engineer patients’ T cells to recognize and attack their cancers..

Kite Pharma selected UMGCCC to be among a small number of pilot sites — and the only one in the Baltimore/Washington region — to offer patients CAR-T cells as a treatment for B cell lymphoma beginning in January 2018. This advanced form of immunotherapy engineers a patient’s own cells so they better recognize and eradicate cancer.

Dr. Cedric Yu and Dr. William Regine invented and developed the GammaPod, a stereotactic radiotherapy system uniquely dedicated to treating early-stage breast tumors. Now under FDA review, this device offers the convenience of fewer treatment sessions and minimizes radiation exposure to the heart and lungs.

Dr. M. Minhaj Siddiqui has led major research studies on the use of MRI/ultrasound fusion-guided biopsy to more accurately diagnose prostate cancer, helping doctors differentiate high-risk cancer from tumors that require only active surveillance.

Dr. Graeme Woodworth received FDA clearance to become the first in the US to open the blood-brain barrier, which protects the brain from toxins but makes it difficult to treat brain cancer with chemotherapy. By using focused ultrasound and microbubbles, UM can disrupt the barrier and inject an agent directly into a brain tumor.

To read more about the Marlene and Stewart Greenebaum Comprehensive Cancer Center, visit www.umms.org/umgccc.


Meet our Volunteer Leadership

Greenebaum Comprehensive Cancer Center's Board of Advisors

Mr. Barry Stoler

Mrs. Marie G. Bowers

Mr. Steven J. Colnitis

Jay C. Feinglass, DMD

Mr. S. Robert Ginsberg

Mrs. Sonya Z. Goodman

Mr. Michael I. Greenebaum

Mr. Erik D. Johnson

Mrs. Donna M. Maykrantz

Mr. Lawrence F. Maykrantz

Mr. Jonathan P. Myers

Ms. Ricka E. Neuman, CPA

Mr. Ian H. Neuman

Mr. Jonathan B. Sevel

Mrs. Roslyn Stoler

Mr. Stuart Weitzman


Emeritus Members

Ms. Paula Rome

Mrs. Edith Wolpoff-Davis